Overexpression of DEP domain containing mTOR-interacting protein correlates with poor prognosis in differentiated thyroid carcinoma

Molecular Medicine Reports

Volumn 4, Issue 5, 2011, Pages 817-823

  Pei, Lei ^a   Xie, Pingfang ^b   Zhou, Enxiang ^b   Yang, Qian ^b   Luo, Yi ^c   Tang, Zhonghua ^b  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c HUNAN CANCER HOSPITAL   (China)

Author keywords

DEP domain containing mammalian target of rapamycin interacting protein; Differentiated thyroid carcinoma; Prognosis

Indexed keywords

DEP DOMAIN CONTAINING MTOR INTERACTING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; UNCLASSIFIED DRUG;

ADULT; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; DIFFERENTIATED THYROID CANCER; ENZYME ACTIVATION; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIVARIATE ANALYSIS; PROGNOSIS; PROTEIN DOMAIN; STATISTICAL SIGNIFICANCE; UNIVARIATE ANALYSIS; WESTERN BLOTTING;

ADULT; AGED; CELL DIFFERENTIATION; CELL LINE, TUMOR; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; RNA, MESSENGER; THYROID GLAND; THYROID NEOPLASMS; TOR SERINE-THREONINE KINASES; YOUNG ADULT;

MAMMALIA;

EID: 79960411515     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2011.503     Document Type: Article

References (26)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 59: 225-249, 2010.
2. Lee J and Soh EY: Differentiated thyroid carcinoma presenting with distant metastasis at initial diagnosis clinical outcomes and prognostic factors. Ann Surg 251: 114-119, 2010.
3. Vorburger SA, Ubersax L, Schmid SW, Balli M, Candinas D and Seiler CA: Long-term-follow-up after complete resection of well-differentiated cancer confined to the thyroid gland. Ann Surg Oncol 16: 2862-2874, 2009.
4. Yip L, Kebebew E, Milas M, et al: Summary statement: utility of molecular marker testing in thyroid cancer. Surgery 148: 1313-1315, 2010.
5. Papotti M, Rodriguez J, de Pompa R, Bartolazzi A and Rosai J: Galectin-3 and HBME-1 expression in well-differentiated thyroid tumors with follicular architecture of uncertain malignant potential. Mod Pathol 18: 541-546, 2005. (Pubitemid 40478118)
6. Chiu CG, Strugnell SS, Griffith OL, et al: Diagnostic utility of galectin-3 in thyroid cancer. Am J Pathol 176: 2067-2081, 2010.
7. Peterson TR, Laplante M, Thoreen CC, et al: DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell 137: 873-886, 2009.
8. Liu M, Wilk SA, Wang A, et al: Resveratrol inhibits mTOR signaling by promoting the interaction between mTOR and DEPTOR. J Biol Chem 285: 36387-36394, 2010.
9. Wullschleger S, Loewith R and Hall MN: TOR signaling in growth and metabolism. Cell 124: 471-484, 2006.
10. Guertin DA and Sabatini DM: Defining the role of mTOR in cancer. Cancer Cell 12: 9-22, 2007.
11. Boyd KD, Walker BA, Wardell CP, Ross FM, Gregory WM, Davies FE and Morgan GJ: High expression levels of the mammalian target of rapamycin inhibitor DEPTOR are predictive of response to thalidomide in myeloma. Leuk Lymphoma 51: 2126-2129, 2010.
12. Sarbassov DD, Guertin DA, Ali SM and Sabatini DM: Phosphorylation and regulation of Akt/pkb by the rictor-mTOR complex. Science 307: 1098-1101, 2005. (Pubitemid 40262113)
13. Zhang S and Yu D: PI (3) king apart PTEN's role in cancer. Clin Cancer Res 16: 4325-4330, 2010.
14. Saji M and Ringel MD: The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors. Mol Cell Endocrinol 321: 20-28, 2010.
15. Liu D, Hou P, Liu Z, Wu G and Xing M: Genetic alterations in the phosphoinositide 3-kinase/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin. Cancer Res 69: 7311-7309, 2009.
16. Yano Y, Uematsu N, Yashiro T, et al: Gene expression profiling identifies platelet-derived growth factor as a diagnostic molecular marker for papillary thyroid carcinoma. Clin Cancer Res 10: 2035-2043, 2004. (Pubitemid 38375564)
17. Bernet VJ, Anderson J, Vaishnav Y, et al: Determination of galectin-3 messenger ribonucleic acid overexpression in papillary thyroid cancer by quantitative reverse transcription-polymerase chain reaction. J Clin Endocrinol Metab 87: 4792-4796, 2002. (Pubitemid 35247077)
18. Cyniak-Magierska A, Wojciechowska-Durczyńska K, Krawczyk-Rusiecka K, Zygmunt A and Lewiński A: Thyroid cancer by quantitative reverse transcription-polymerase chain assessment of RET/PTC1 and RET/PTC3 rearrangements in fine-needle aspiration biopsy specimens collected from patients with Hashimoto's thyroiditis. Thyroid Res 4: 5, 2011.
19. Argani P, Hicks J, de Marzo AM, et al: Xp11 translocation renal cell carcinoma (RCC): extended immunohistochemical profile emphasizing novel RCC markers. Am J Surg Pathol 34: 1295-1303, 2010.
20. Stern HM, Padilla M, Wagner K, Amler L and Ashkenazi A: Development of immunohistochemistry assays to assess GALNT14 and FUT3/6 in clinical trials of dulanermin and drozitumab. Clin Cancer Res 16: 1587-1596, 2010.
21. Zhu ZH, Sun BY, Ma Y, et al: Three immunomarker support vector machines-based prognostic classifiers for stage IB non-small-cell lung cancer. J Clin Oncol: 27: 1091-1099, 2009.
22. Carrasco DR, Tonon G, Huang Y, et al: High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell 9: 313-325, 2006.
23. Foster H, Coley HM, Goumenou A, Pados G, Harvey A and Karteris E: Differential expression of mTOR signalling components in drug resistance in ovarian cancer. Anticancer Res 30: 3529-3534, 2010.
24. Clague MJ and Urbé S: Ubiquitin: same molecule, different degradation pathway. Cell 143: 682-685, 2010.
25. Qin S, Taglienti M, Nauli SM, Contrino L, Takakura A, Zhou J and Kreidberg JA: Failure to ubiquitinate c-Met leads to hyperactivation of mTOR signaling in a mouse model of autosomal dominant polycystic kidney disease. J Clin Invest 120: 3617-3628, 2010.
26. Maeurer C, Holland S, Pierre S, Potstada W and Scholich K: Sphingosine-1-phosphate induced mTOR-activation is mediated by the E3-ubiquitin ligase PAM. Cell Signal 21: 293-300, 2009.